Deciduous Therapeutics Inc. has disclosed compounds with the ability to activate invariant natural killer T cells (iNKT) and that are reported to be useful for the treatment of obesity.

Cambridge Enterprise Ltd. has synthesized benzo[c][2,6]naphthyridine derivatives acting as casein kinase II isoform alpha prime (CK2α′) inhibitors reported to be useful for the treatment of cancer, diabetes, ischemia, neurodegeneration, viral infections cardiovascular and inflammatory disorders, among others.

Eli Lilly & Co. has identified new fibroblast growth factor receptor 3 (FGFR3) inhibitors reported to be useful for the treatment of achondroplasia, cancer, pulmonary fibrosis, systemic scleroderma and thanatophoric dysplasia, among other disorders.

The University of Michigan has synthesized new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked estrogen receptor (ER) targeting moiety reported to be useful for the treatment of breast cancer.

The State University of New York has presented new antibody-drug conjugates (ADCs) consisting of trastuzumab antibody targeting human epidermal growth factor receptor 2 (HER2) covalently linked to Toll-like receptor 7 (TLR7) and/or TLR8 agonists through a linker reported to be useful for the treatment of cancer and infections.

Hillstream Biopharma Inc. has described new salinomycin derivatives acting as angiogenesis inhibitors reported to be useful for the treatment of cancer.

Boundless Bio Inc. has divulged new ribonucleoside-diphosphate reductase (RNR) inhibitors reported to be useful for the treatment of cancer.

The University of Antwerp has identified new quinazolin-4-one and thieno[2,3-d]pyrimidin-4-one HER4 (ERBB4) inhibitors reported to be useful for the treatment of heart failure, cancer, fibrosis, and metabolic and inflammatory disorders.

Genfleet Therapeutics (Shanghai) Inc. has synthesized new mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.

Convalife (Shanghai) Health Technology Co. Ltd. has presented new thyroid hormone receptor α (TR-α) and (TR-β) agonists reported to be useful for the treatment of nonalcoholic fatty liver disease, obesity, liver fibrosis, type 2 diabetes and hypercholesterolemia.